ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
AEON Biopharma Inc

AEON Biopharma Inc (AEON)

0.76
-0.009
(-1.17%)
Closed September 10 4:00PM
0.76
0.00
(0.00%)
After Hours: 7:50PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.76
Bid
-
Ask
-
Volume
52,404
0.74 Day's Range 0.8121
0.7066 52 Week Range 17.17
Market Cap
Previous Close
0.769
Open
0.8121
Last Trade
257
@
0.76
Last Trade Time
Financial Volume
$ 40,269
VWAP
0.768436
Average Volume (3m)
1,888,501
Shares Outstanding
39,522,238
Dividend Yield
-
PE Ratio
1.25
Earnings Per Share (EPS)
0.61
Revenue
52.75M
Net Profit
24.05M

About AEON Biopharma Inc

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Show more

Sector
Pharmaceutical Preparations
Industry
Blank Checks
Headquarters
Wilmington, Delaware, USA
Founded
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was $0.77. Over the last year, AEON Biopharma shares have traded in a share price range of $ 0.7066 to $ 17.17.

AEON Biopharma currently has 39,522,238 shares outstanding. The market capitalization of AEON Biopharma is $30.39 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 1.25.

AEON Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-50.80.860.7066904930.8150153CS
4-0.29-27.6190476191.051.10.7066933110.91990207CS
12-0.65-46.09929078011.413.740.706618885012.43638982CS
26-10.72-93.379790940811.4817.170.70669155732.63370966CS
52-4.17-84.5841784994.9317.170.70664704792.76348951CS
156-9.38-92.504930966510.1417.170.70664344232.9307577CS
260-9.38-92.504930966510.1417.170.70664344232.9307577CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BURUNuburu Inc
$ 0.67
(29.59%)
12.89M
VINEFresh Vine Wine Inc
$ 0.4988
(23.16%)
473.69k
MSOXAdvisorshares Msos 2x Daily ETF
$ 2.33
(22.63%)
5.09M
RYDERyde Group Ltd
$ 20.24
(16.79%)
5.64M
BTCLT Rex 2X Long Bitcoin Daily Target ETF
$ 21.76
(14.29%)
204.75k
VHAIVocodia Holdings Corp
$ 0.0318
(-18.46%)
52.93M
SBITProshares Ultrashort Bitcoin ETF
$ 40.06
(-13.59%)
782.29k
BTCZT Rex 2X Inverse Bitcoin Daily Target ETF
$ 20.83
(-12.84%)
24.64k
UVIX2x Long VIX Futures ETF
$ 5.37
(-12.68%)
24.83M
ETHDProshares Ultrashort Ether ETF
$ 72.61
(-11.38%)
16.99k
SOXLDirexion Daily Semiconductor Bull 3X Shares
$ 27.43
(5.66%)
84.47M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
$ 28.97
(-6.03%)
55.23M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
$ 7.80
(-3.23%)
53.01M
VHAIVocodia Holdings Corp
$ 0.0318
(-18.46%)
52.93M
SHProShares Short S&P500 New
$ 11.52
(-1.12%)
40.66M

AEON Discussion

View Posts
Monksdream Monksdream 4 days ago
AEON new 52=week low
👍️0
willlbone willlbone 1 month ago
Dilution.
👍️0
glenn1919 glenn1919 2 months ago
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 2 months ago
AEON under $3
👍️0
glenn1919 glenn1919 2 months ago
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 2 months ago
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 2 months ago
AEON new 52 week low
👍️0
Monksdream Monksdream 3 months ago
AEON new 52 week low
👍️0
DewDiligence DewDiligence 3 months ago
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 4 months ago
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 4 months ago
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 4 months ago
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 4 months ago
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 5 months ago
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 5 months ago
What happened here today?
👍️0
DewDiligence DewDiligence 5 months ago
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 6 months ago
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 6 months ago
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 8 months ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 10 months ago
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 11 months ago
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 year ago
Nice run today.
👍️0
DewDiligence DewDiligence 1 year ago
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 1 year ago
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 1 year ago
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 1 year ago
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 1 year ago
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 1 year ago
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0

Your Recent History

Delayed Upgrade Clock